March 25, 2022
Yakult Honsha said on March 24 that it has filed a new drug application in Japan for its oral phosphoinositide 3-kinase (PI3K) inhibitor duvelisib for the treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The submission of...read more